Biohaven (BHVN) investor relations material

Executive summary

• Advanced late-stage clinical programs in immunology, obesity, neuroscience, and oncology, with strategic prioritization of Kv7 ion channel modulation, MODE/TRAP degraders, and myostatin-activin pathway agents as of Q4 2025.

• Multiple pivotal trials progressed, including epilepsy and obesity studies with topline data expected in 2H 2026, and new pivotal studies for IgA nephropathy and Graves' disease to begin by mid-2026.

• Progress in early Parkinson's and endometrial cancer trials, with no dose-limiting toxicities in the FGFR3 ADC program.

• Five presentations at AAN Annual Meeting highlighted innovation in neuroscience and immunology.

• No revenue generated from product sales to date; operations funded by equity and debt financings.

Financial highlights

• Net loss for Q1 2026 was $130.5 million, a significant improvement from $221.7 million in Q1 2025, driven by lower R&D and G&A expenses.

• R&D expenses decreased to $103.8 million from $187.6 million year-over-year, reflecting strategic reprioritization and lower non-cash share-based compensation.

• G&A expenses fell to $26.6 million from $34.0 million year-over-year, mainly due to reduced share-based compensation.

• Cash, cash equivalents, marketable securities, and restricted cash totaled $351.8 million as of March 31, 2026.

• Non-GAAP adjusted net loss was $102.2 million ($0.69/share) vs. $166.8 million ($1.64/share) year-over-year.

Outlook and guidance

• Topline results for epilepsy and obesity programs expected in 2H 2026.

• Pivotal studies for IgA nephropathy and Graves' disease to begin mid-2026.

• Cash, cash equivalents, and marketable securities expected to fund operations for at least one year from the reporting date.

• Continued significant expenses anticipated as late-stage clinical trials progress and commercialization preparations advance.

• Additional funding may be required for future growth, acquisitions, or if product sales do not materialize.